Key Points
-
Combinations of biomarkers perform better than single biomarkers for predicting pre-eclampsia, but require external validation before they can be used routinely
-
Potentially effective interventions to prevent pre-eclampsia in patients at risk include early administration of low-dose aspirin or L-arginine in combination with oral antioxidants (vitamins C and E)
-
Maternal plasma levels of angiogenic and antiangiogenic factors identify most patients who will develop early pre-eclampsia, correlate with disease severity and have prognostic value for maternal and/or perinatal complications
-
Management of pre-eclampsia includes control of hypertension, prevention of seizures and timely delivery; steroids are administered to enhance fetal lung maturity if induction of labour before 34 weeks is contemplated
-
In pre-eclampsia at ≥37 weeks of gestation, delivery effectively optimizes pregnancy outcomes; for preterm gestations, the risk of continued pregnancy must be balanced against that of premature birth
-
Women with pre-eclampsia are at increased risk of developing cardiovascular disease, including chronic hypertension, stroke, coronary artery disease, diabetes and end-stage renal disease later in life
Abstract
An antiangiogenic state might constitute a terminal pathway for the multiple aetiologies of pre-eclampsia, especially those resulting from placental abnormalities. The levels of angiogenic and antiangiogenic proteins in maternal blood change prior to a diagnosis of pre-eclampsia, correlate with disease severity and have prognostic value in identifying women who will develop maternal and/or perinatal complications. Potential interventions exist to ameliorate the imbalance of angiogenesis and, hence, might provide opportunities to improve maternal and/or perinatal outcomes in pre-eclampsia. Current strategies for managing pre-eclampsia consist of controlling hypertension, preventing seizures and timely delivery of the fetus. Prediction of pre-eclampsia in the first trimester is of great interest, as early administration of aspirin might reduce the risk of pre-eclampsia, albeit modestly. Combinations of biomarkers typically predict pre-eclampsia better than single biomarkers; however, the encouraging initial results of biomarker studies require external validation in other populations before they can be used to facilitate intervention in patients identified as at increased risk. Angiogenic and antiangiogenic factors might also be useful in triage of symptomatic patients with suspected pre-eclampsia, differentiating pre-eclampsia from exacerbations of pre-existing medical conditions and performing risk assessment in asymptomatic women. This Review article discusses the performance of predictive and prognostic biomarkers for pre-eclampsia, current strategies for preventing and managing the condition and its long-term consequences.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Chaiworapongsa, T., Chaemsaithong, P., Korzeniewski, S. J., Yeo, L. & Romero, R. Pre-eclampsia part 1: current understanding of its pathophysiology. Nat. Rev. Nephrol. http://dx.doi.org/10.1038/nrneph.2014.102.
Kuc, S. et al. Evaluation of 7 serum biomarkers and uterine artery Doppler ultrasound for first-trimester prediction of preeclampsia: a systematic review. Obstet. Gynecol. Surv. 66, 225–239 (2011).
Askie, L. M., Duley, L., Henderson-Smart, D. J. & Stewart, L. A. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet 369, 1791–1798 (2007).
Bujold, E. et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet. Gynecol. 116, 402–414 (2010).
Vadillo-Ortega, F. et al. Effect of supplementation during pregnancy with L-arginine and antioxidant vitamins in medical food on pre-eclampsia in high risk population: randomised controlled trial. BMJ 342, d2901 (2011).
Roberge, S. et al. Early administration of low-dose aspirin for the prevention of severe and mild preeclampsia: a systematic review and meta-analysis. Am. J. Perinatol. 29, 551–556 (2012).
Goel, A. & Rana, S. Angiogenic factors in preeclampsia: potential for diagnosis and treatment. Curr. Opin. Nephrol. Hypertens. 22, 643–650 (2013).
Hagmann, H., Thadhani, R., Benzing, T., Karumanchi, S. A. & Stepan, H. The promise of angiogenic markers for the early diagnosis and prediction of preeclampsia. Clin. Chem. 58, 837–845 (2012).
Silasi, M., Cohen, B., Karumanchi, S. A. & Rana, S. Abnormal placentation, angiogenic factors, and the pathogenesis of preeclampsia. Obstet. Gynecol. Clin. North Am. 37, 239–253 (2010).
Smith, G. C. & Wear, H. The perinatal implications of angiogenic factors. Curr. Opin. Obstet. Gynecol. 21, 111–116 (2009).
Roberts, J. M. & Bell, M. J. If we know so much about preeclampsia, why haven't we cured the disease? J. Reprod. Immunol. 99, 1–9 (2013).
Chaiworapongsa, T. et al. Maternal plasma concentrations of angiogenic/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia. J. Matern. Fetal Neonatal Med. 24, 1187–1207 (2011).
Moore, A. G. et al. Angiogenic biomarkers for prediction of maternal and neonatal complications in suspected preeclampsia. J. Matern. Fetal Neonatal Med. 25, 2651–2657 (2012).
Rana, S. et al. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 125, 911–919 (2012).
Chaiworapongsa, T. et al. Plasma concentrations of angiogenic/anti-angiogenic factors have prognostic value in women presenting with suspected preeclampsia to the obstetrical triage area: a prospective study. J. Matern. Fetal Neonatal Med. 7, 132–144 (2013).
Moore Simas, T. A. et al. Angiogenic factors for the prediction of preeclampsia in high-risk women. Am. J. Obstet. Gynecol. 197, 244.e1–244.e8 (2007).
Li, Z. et al. Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia. Hypertension 50, 686–692 (2007).
Gilbert, J. S. et al. Recombinant vascular endothelial growth factor 121 infusion lowers blood pressure and improves renal function in rats with placentalischemia-induced hypertension. Hypertension 55, 380–385 (2010).
Kumasawa, K. et al. Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model. Proc. Natl Acad. Sci. USA 108, 1451–1455 (2011).
Thadhani, R. et al. Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation 124, 940–950 (2011).
Woods, A. K. et al. Adenoviral delivery of VEGF121 early in pregnancy prevents spontaneous development of preeclampsia in BPH/5 mice. Hypertension 57, 94–102 (2011).
Jiang, X. et al. A higher maternal choline intake among third-trimester pregnant women lowers placental and circulating concentrations of the antiangiogenic factor fms-like tyrosine kinase-1 (sFLT1). FASEB J. 27, 1245–1253 (2013).
Brown, M. C. et al. Cardiovascular disease risk in women with pre-eclampsia: systematic review and meta-analysis. Eur. J. Epidemiol. 28, 1–19 (2013).
Vikse, B. E., Irgens, L. M., Leivestad, T., Skjaerven, R. & Iversen, B. M. Preeclampsia and the risk of end-stage renal disease. N. Engl. J. Med. 359, 800–809 (2008).
Forest, J. C. et al. Candidate biochemical markers for screening of pre-eclampsia in early pregnancy. Clin. Chem. Lab. Med. 50, 973–984 (2012).
Anderson, U. D., Olsson, M. G., Kristensen, K. H., Akerstrom, B. & Hansson, S. R. Review: Biochemical markers to predict preeclampsia. Placenta 33 (Suppl.), S42–S47 (2012).
Spencer, K., Cowans, N. J., Chefetz, I., Tal, J. & Meiri, H. First-trimester maternal serum PP-13, PAPP-A and second-trimester uterine artery Doppler pulsatility index as markers of pre-eclampsia. Ultrasound Obstet. Gynecol. 29, 128–134 (2007).
Ong, C. Y., Liao, A. W., Spencer, K., Munim, S. & Nicolaides, K. H. First trimester maternal serum free beta human chorionic gonadotrophin and pregnancy associated plasma protein A as predictors of pregnancy complications. BJOG 107, 1265–1270 (2000).
Spencer, K., Yu, C. K., Cowans, N. J., Otigbah, C. & Nicolaides, K. H. Prediction of pregnancy complications by first-trimester maternal serum PAPP-A and free β-hCG and with second-trimester uterine artery Doppler. Prenat. Diagn. 25, 949–953 (2005).
Odibo, A. O. et al. Placental volume and vascular flow assessed by 3D power Doppler and adverse pregnancy outcomes. Placenta 32, 230–234 (2011).
Plasencia, W., Maiz, N., Poon, L., Yu, C. & Nicolaides, K. H. Uterine artery Doppler at 11 + 0 to 13 + 6 weeks and 21 + 0 to 24 + 6 weeks in the prediction of pre-eclampsia. Ultrasound Obstet. Gynecol. 32, 138–146 (2008).
Romero, R. et al. First-trimester maternal serum PP13 in the risk assessment for preeclampsia. Am. J. Obstet. Gynecol. 199, 122.e121–122.e111 (2008).
Nicolaides, K. H. et al. A novel approach to first-trimester screening for early pre-eclampsia combining serum PP-13 and Doppler ultrasound. Ultrasound Obstet. Gynecol. 27, 13–17 (2006).
Akolekar, R., Syngelaki, A., Beta, J., Kocylowski, R. & Nicolaides, K. H. Maternal serum placental protein 13 at 11–13 weeks of gestation in preeclampsia. Prenat. Diagn. 29, 1103–1108 (2009).
Stamatopoulou, A., Cowans, N. J., Matwejew, E., von Kaisenberg, C. & Spencer, K. Placental protein-13 and pregnancy-associated plasma protein-A as first trimester screening markers for hypertensive disorders and small for gestational age outcomes. Hypertens. Pregnancy 30, 384–395 (2011).
Akolekar, R., Syngelaki, A., Sarquis, R., Zvanca, M. & Nicolaides, K. H. Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11–13 weeks. Prenat. Diagn. 31, 66–74 (2011).
Wright, D., Akolekar, R., Syngelaki, A., Poon, L. C. & Nicolaides, K. H. A competing risks model in early screening for preeclampsia. Fetal Diagn. Ther. 32, 171–178 (2012).
Akolekar, R., Syngelaki, A., Poon, L., Wright, D. & Nicolaides, K. H. Competing risks model in early screening for preeclampsia by biophysical and biochemical markers. Fetal Diagn. Ther. 33, 8–15 (2013).
Pedrosa, A. C. & Matias, A. Screening for pre-eclampsia: a systematic review of tests combining uterine artery Doppler with other markers. J. Perinat. Med. 39, 619–635 (2011).
Herraiz, I. et al. Application of a first-trimester prediction model for pre-eclampsia based on uterine arteries and maternal history in high-risk pregnancies. Prenat. Diagn. 29, 1123–1129 (2009).
Farina, A. et al. Prospective evaluation of ultrasound and biochemical-based multivariable models for the prediction of late pre-eclampsia. Prenat. Diagn. 31, 1147–1152 (2011).
Smith, G. C. Researching new methods of screening for adverse pregnancy outcome: lessons from pre-eclampsia. PLoS Med. 9, e1001274 (2012).
Rasanen, J. et al. Comprehensive maternal serum proteomic profiles of preclinical and clinical preeclampsia. J. Proteome Res. 9, 4274–4281 (2010).
Carty, D. M. et al. Urinary proteomics for prediction of preeclampsia. Hypertension 57, 561–569 (2011).
Kenny, L. C. et al. Robust early pregnancy prediction of later preeclampsia using metabolomic biomarkers. Hypertension 56, 741–749 (2010).
Bahado-Singh, R. O. et al. First-trimester metabolomic detection of late-onset preeclampsia. Am. J. Obstet. Gynecol. 208, 58.e1–58.e7 (2013).
Bahado-Singh, R. O. et al. Metabolomics and first-trimester prediction of early-onset preeclampsia. J. Matern. Fetal Neonatal Med. 25, 1840–1847 (2012).
Leung, T. N., Zhang, J., Lau, T. K., Chan, L. Y. & Lo, Y. M. Increased maternal plasma fetal DNA concentrations in women who eventually develop preeclampsia. Clin. Chem. 47, 137–139 (2001).
Farina, A. et al. Cell-free fetal DNA (SRY locus) concentration in maternal plasma is directly correlated to the time elapsed from the onset of preeclampsia to the collection of blood. Prenat. Diagn. 24, 293–297 (2004).
Purwosunu, Y. et al. Cell-free mRNA concentrations of CRH, PLAC1, and selectin-P are increased in the plasma of pregnant women with preeclampsia. Prenat. Diagn. 27, 772–777 (2007).
Purwosunu, Y. et al. Prediction of preeclampsia by analysis of cell-free messenger RNA in maternal plasma. Am. J. Obstet. Gynecol. 200, 386.e1–386.e7 (2009).
Levine, R. J. et al. Two-stage elevation of cell-free fetal DNA in maternal sera before onset of preeclampsia. Am. J. Obstet. Gynecol. 190, 707–713 (2004).
Crowley, A. et al. Free fetal DNA is not increased before 20 weeks in intrauterine growth restriction or pre-eclampsia. Prenat. Diagn. 27, 174–179 (2007).
Poon, L. C., Musci, T., Song, K., Syngelaki, A. & Nicolaides, K. H. Maternal plasma cell-free fetal and maternal DNA at 11–13 weeks' gestation: relation to fetal and maternal characteristics and pregnancy outcomes. Fetal Diagn. Ther. 33, 215–223 (2013).
Sekizawa, A. et al. Prediction of pre-eclampsia by an analysis of placenta-derived cellular mRNA in the blood of pregnant women at 15–20 weeks of gestation. BJOG. 117, 557–564 (2010).
Farina, A. et al. Performance of messenger RNAs circulating in maternal blood in the prediction of preeclampsia at 10–14 weeks. Am. J. Obstet. Gynecol. 203, 575.e1–575.e7 (2010).
von Dadelszen, P. et al. Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model. Lancet 377, 219–227 (2011).
Payne, B. et al. Performance of the fullPIERS model in predicting adverse maternal outcomes in pre-eclampsia using patient data from the PIERS (Pre-eclampsia Integrated Estimate of RiSk) cohort, collected on admission. BJOG 120, 113–118 (2013).
Maynard, S. E. et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J. Clin. Invest. 111, 649–658 (2003).
Venkatesha, S. et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat. Med. 12, 642–649 (2006).
Kusanovic, J. P. et al. A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J. Matern. Fetal Neonatal Med. 22, 1021–1038 (2009).
Moore Simas, T. A. et al. Angiogenic biomarkers for prediction of early preeclampsia onset in high-risk women. J. Matern Fetal Neonatal Med. 27, 1038–1048 (2014).
Levine, R. J. et al. Circulating angiogenic factors and the risk of preeclampsia. N. Engl. J. Med. 350, 672–683 (2004).
Chaiworapongsa, T. et al. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. Am. J. Obstet. Gynecol. 190, 1541–1550 (2004).
Rana, S. et al. Plasma concentrations of soluble endoglin versus standard evaluation in patients with suspected preeclampsia. PLoS ONE 7, e48259 (2012).
Chappell, L. C. et al. Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: a prospective multicenter study. Circulation 128, 2121–2131 (2013).
Rana, S. et al. Clinical characterization and outcomes of preeclampsia with normal angiogenic profile. Hypertens. Pregnancy 32, 189–201 (2013).
Powers, R. W. et al. Low placental growth factor across pregnancy identifies a subset of women with preterm preeclampsia: type 1 versus type 2 preeclampsia? Hypertension 60, 239–246 (2012).
Rana, S., Karumanchi, S. A. & Lindheimer, M. D. Angiogenic factors in diagnosis, management, and research in preeclampsia. Hypertension 63, 198–202 (2014).
Chaiworapongsa, T. et al. Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J. Matern. Fetal Neonatal Med. 17, 3–18 (2005).
Sibiude, J. et al. Placental growth factor for the prediction of adverse outcomes in patients with suspected preeclampsia or intrauterine growth restriction. PLoS ONE 7, e50208 (2012).
Schnettler, W. et al. Cost and resource implications with serum angiogenic factor estimation in the triage of pre-eclampsia. BJOG 120, 1224–1232 (2013).
Rolfo, A. et al. Chronic kidney disease may be differentially diagnosed from preeclampsia by serum biomarkers. Kidney Int. 83, 177–181 (2013).
Di Marco, G. S. et al. The soluble VEGF receptor sFlt1 contributes to endothelial dysfunction in CKD. J. Am. Soc. Nephrol. 20, 2235–2245 (2009).
Williams, W. W. Jr, Ecker, J. L., Thadhani, R. I. & Rahemtullah, A. Case records of the Massachusetts General Hospital. Case 38–2005. A 29-year-old pregnant woman with the nephrotic syndrome and hypertension. N. Engl. J. Med. 353, 2590–2600 (2005).
Qazi, U., Lam, C., Karumanchi, S. A. & Petri, M. Soluble Fms-like tyrosine kinase associated with preeclampsia in pregnancy in systemic lupus erythematosus. J. Rheumatol. 35, 631–634 (2008).
Shan, H. Y. et al. Use of circulating antiangiogenic factors to differentiate other hypertensive disorders from preeclampsia in a pregnant woman on dialysis. Am. J. Kidney Dis. 51, 1029–1032 (2008).
Masuyama, H. et al. Circulating angiogenic factors in preeclampsia, gestational proteinuria, and preeclampsia superimposed on chronic glomerulonephritis. Am. J. Obstet. Gynecol. 194, 551–556 (2006).
Masuyama, H. et al. Superimposed preeclampsia in women with chronic kidney disease. Gynecol. Obstet. Invest. 74, 274–281 (2012).
Widmer, M. et al. Mapping the theories of preeclampsia and the role of angiogenic factors: a systematic review. Obstet. Gynecol. 109, 168–180 (2007).
Sibai, B. M. et al. Serum inhibin A and angiogenic factor levels in pregnancies with previous preeclampsia and/or chronic hypertension: are they useful markers for prediction of subsequent preeclampsia? Am. J. Obstet. Gynecol. 199, 268.e1–268.e9 (2008).
McElrath, T. F. et al. Longitudinal evaluation of predictive value for preeclampsia of circulating angiogenic factors through pregnancy. Am. J. Obstet. Gynecol. 207, 407.e1–407.e7 (2012).
Myatt, L. et al. Can changes in angiogenic biomarkers between the first and second trimesters of pregnancy predict development of pre-eclampsia in a low-risk nulliparous patient population? BJOG 120, 1183–1191 (2013).
Myers, J. et al. Angiogenic factors combined with clinical risk factors to predict preterm pre-eclampsia in nulliparous women: a predictive test accuracy study. BJOG 120, 1215–1223 (2013).
Chaiworapongsa, T. et al. Maternal plasma concentrations of angiogenic/antiangiogenic factors in the third trimester of pregnancy to identify the patient at risk for stillbirth at or near term and severe late preeclampsia. Am. J. Obstet. Gynecol. 208, 287.e1–287.e15 (2013).
Lai, J., Syngelaki, A., Poon, L. C., Nucci, M. & Nicolaides, K. H. Maternal serum soluble endoglin at 30–33 weeks in the prediction of preeclampsia. Fetal Diagn. Ther. 33, 149–155 (2013).
Kleinrouweler, C. E. et al. Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms-like tyrosine kinase 1 and soluble endoglin in the prediction of pre-eclampsia: a systematic review and meta-analysis. BJOG 119, 778–787 (2012).
Powers, R. W. et al. Soluble fms-Like tyrosine kinase 1 (sFlt1), endoglin and placental growth factor (PlGF) in preeclampsia among high risk pregnancies. PLoS ONE 5, e13263 (2010).
Driscoll, D. A. & Gross, S. Clinical practice. Prenatal screening for aneuploidy. N. Engl. J. Med. 360, 2556–2562 (2009).
American College of Obstetricians and Gynecologists Task Force on Hypertension in Pregnancy, Hypertension in Pregnancy [online], (2013).
Blackwell, S. C. et al. Labor induction for the preterm severe pre-eclamptic patient: is it worth the effort? J. Matern. Fetal Med. 10, 305–311 (2001).
Sibai, B. M. Evaluation and management of severe preeclampsia before 34 weeks' gestation. Am. J. Obstet. Gynecol. 205, 191–198 (2011).
Committee Opinion no. 514: emergent therapy for acute-onset, severe hypertension with preeclampsia or eclampsia. Obstet. Gynecol. 118, 1465–1468 (2011).
Martin, J. N. Jr et al. Stroke and severe preeclampsia and eclampsia: a paradigm shift focusing on systolic blood pressure. Obstet. Gynecol. 105, 246–254 (2005).
Redman, C. W. Hypertension in pregnancy: the NICE guidelines. Heart 97, 1967–1969 (2011).
Magee, L. A., Helewa, M., Moutquin, J. M. & von Dadelszen, P. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. J. Obstet. Gynaecol. Can. 30 (Suppl. 1), S1–S48 (2008).
Lowe, S. A. et al. Guidelines for the management of hypertensive disorders of pregnancy 2008. Aust. NZ J. Obstet. Gynaecol. 49, 242–246 (2009).
Gogarten, W. Preeclampsia and anaesthesia. Curr. Opin. Anaesthesiol. 22, 347–351 (2009).
Umans, J. G., Abalos, E. J. & Lindheimer, M. D. in Chesley's Hypertensive Disorders in Pregnancy (eds Lindheimer, M. D., Roberts, J. M. & Cunningham, G. C.) 369–388 (Elsevier, 2009).
Duley, L., Meher, S. & Jones, L. Drugs for treatment of very high blood pressure during pregnancy. Cochrane Database of Systematic Reviews, Issue 3. Art. No.: CD001449. http://dx.doi.org/10.1002/14651858.CD001449.pub2.
Sibai, B. M. Diagnosis, prevention, and management of eclampsia. Obstet. Gynecol. 105, 402–410 (2005).
Smith, J. M. et al. An integrative review of the side effects related to the use of magnesium sulfate for pre-eclampsia and eclampsia management. BMC Pregnancy Childbirth 13, 34 (2013).
Which anticonvulsant for women with eclampsia? Evidence from the Collaborative Eclampsia Trial. Lancet 345, 1455–1463 (1995).
Altman, D. et al. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet 359, 1877–1890 (2002).
Duley, L., Gulmezoglu, A. M., Henderson-Smart, D. J. & Chou, D. Magnesium sulphate and other anticonvulsants for women with pre-eclampsia. Cochrane Database of Systematic Reviews, Issue 2. Art. No.: CD000025. http://dx.doi.org/10.1002/14651858.CD000025.
Sibai, B. M. & Cunningham, F. G. in Chesley's Hypertensive Disorders in Pregnancy (eds Lindheimer, M. D., Roberts, J. M. & Cunningham, G. C.) 214–225 (Elsevier, 2009).
Walsh, S. W. Preeclampsia: an imbalance in placental prostacyclin and thromboxane production. Am. J. Obstet. Gynecol. 152, 335–340 (1985).
Romero, R., Lockwood, C., Oyarzun, E. & Hobbins, J. C. Toxemia: new concepts in an old disease. Semin. Perinatol. 12, 302–323 (1988).
[No authors listed] CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group. Lancet 343, 619–629 (1994).
Duley, L., Henderson-Smart, D. J., Meher, S. & King, J. F. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database of Systematic Reviews, Issue 2. Art. No.: CD004659. http://dx.doi.org/10.1002/14651858.CD004659.pub2.
Villa, P. M. et al. Aspirin in the prevention of pre-eclampsia in high-risk women: a randomised placebo-controlled PREDO Trial and a meta-analysis of randomised trials. BJOG 120, 64–74 (2013).
Conde-Agudelo, A., Romero, R., Kusanovic, J. P. & Hassan, S. S. Supplementation with vitamins C and E during pregnancy for the prevention of preeclampsia and other adverse maternal and perinatal outcomes: a systematic review and metaanalysis. Am. J. Obstet. Gynecol. 204, 503.e1–503.e12 (2011).
Belizan, J. M. & Villar, J. The relationship between calcium intake and edema-, proteinuria-, and hypertension-getosis: an hypothesis. Am. J. Clin. Nutr. 33, 2202–2210 (1980).
Lopez-Jaramillo, P., Narvaez, M., Felix, C. & Lopez, A. Dietary calcium supplementation and prevention of pregnancy hypertension. Lancet 335, 293 (1990).
Villar, J. & Repke, J. T. Calcium supplementation during pregnancy may reduce preterm delivery in high-risk populations. Am. J. Obstet. Gynecol. 163, 1124–1131 (1990).
Belizan, J. M., Villar, J., Gonzalez, L., Campodonico, L. & Bergel, E. Calcium supplementation to prevent hypertensive disorders of pregnancy. N. Engl. J. Med. 325, 1399–1405 (1991).
Levine, R. J. et al. Trial of calcium to prevent preeclampsia. N. Engl. J. Med. 337, 69–76 (1997).
Hofmeyr, G. J., Lawrie, T. A., Atallah, A. N. & Duley, L. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database of Systematic Reviews, Issue 8. Art. No.: CD001059. http://dx.doi.org/10.1002/14651858.CD001059.pub3.
Patrelli, T. S. et al. Calcium supplementation and prevention of preeclampsia: a meta-analysis. J. Matern. Fetal Neonatal Med. 25, 2570–2574 (2012).
Costantine, M. M. & Cleary, K. Pravastatin for the prevention of preeclampsia in high-risk pregnant women. Obstet. Gynecol. 121, 349–353 (2013).
Loebstein, R., Lalkin, A. & Koren, G. Pharmacokinetic changes during pregnancy and their clinical relevance. Clin. Pharmacokinet. 33, 328–343 (1997).
Edison, R. J. & Muenke, M. Mechanistic and epidemiologic considerations in the evaluation of adverse birth outcomes following gestational exposure to statins. Am. J. Med. Genet. A 131, 287–298 (2004).
Nanovskaya, T. N. et al. Transplacental transfer and distribution of pravastatin. Am. J. Obstet. Gynecol. 209, 373.e1–373.e5 (2013).
Bar, J. et al. Microalbuminuria after pregnancy complicated by pre-eclampsia. Nephrol. Dial. Transplant. 14, 1129–1132 (1999).
Reiter, L., Brown, M. A. & Whitworth, J. A. Hypertension in pregnancy: the incidence of underlying renal disease and essential hypertension. Am. J. Kidney Dis. 24, 883–887 (1994).
Williams, D. & Davison, J. Chronic kidney disease in pregnancy. BMJ 336, 211–215 (2008).
Fisher, K. A., Luger, A., Spargo, B. H. & Lindheimer, M. D. Hypertension in pregnancy: clinical-pathological correlations and remote prognosis. Medicine (Baltimore) 60, 267–276 (1981).
Carty, D. M., Delles, C. & Dominiczak, A. F. Preeclampsia and future maternal health. J. Hypertens. 28, 1349–1355 (2010).
Williams, D. Long-term complications of preeclampsia. Semin. Nephrol. 31, 111–122 (2011).
Koopmans, C. M. et al. Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks' gestation (HYPITAT): a multicentre, open-label randomised controlled trial. Lancet 374, 979–988 (2009).
Tajik, P. et al. Should cervical favourability play a role in the decision for labour induction in gestational hypertension or mild pre-eclampsia at term? An exploratory analysis of the HYPITAT trial. BJOG 119, 1123–1130 (2012).
Pauli, J. M. et al. Management of gestational hypertension - the impact of HYPITATa. J. Perinat. Med. 41, 415–420 (2013).
Smith, P., Anthony, J. & Johanson, R. Nifedipine in pregnancy. BJOG 107, 299–307 (2000).
Hypertension in pregnancy: executive summary. Obstet. Gynecol. 122, 1122–1131 (2013).
Acknowledgements
The authors' research is supported partly by the Perinatology Research Branch, Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, Department of Health and Human Services (NICHD/NIH/DHHS) and partly with Federal funding from the NICHD and NIH under contract no. HHSN275201300006C.
Author information
Authors and Affiliations
Contributions
All authors researched data for the article, made substantial contribution to discussion of the content, wrote, reviewed and edited the manuscript before submission.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Chaiworapongsa, T., Chaemsaithong, P., Korzeniewski, S. et al. Pre-eclampsia part 2: prediction, prevention and management. Nat Rev Nephrol 10, 531–540 (2014). https://doi.org/10.1038/nrneph.2014.103
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2014.103
This article is cited by
-
Low-molecular-weight heparin for the prevention of preeclampsia in high-risk pregnancies without thrombophilia: a systematic review and meta-analysis
BMC Pregnancy and Childbirth (2024)
-
MicroRNA-495 suppresses pre-eclampsia via activation of p53/PUMA axis
Cell Death Discovery (2022)
-
Increased risk of preeclampsia after use of paracetamol during pregnancy – causal or coincidence?
BMC Pregnancy and Childbirth (2021)
-
Incidence of Adverse Drug Reactions in High-Risk Pregnancy: A Prospective Cohort Study in Obstetric Intensive Care
European Journal of Clinical Pharmacology (2020)
-
Characterizing placental stiffness using ultrasound shear-wave elastography in healthy and preeclamptic pregnancies
Archives of Gynecology and Obstetrics (2020)